section name header

Evidence summaries

Corticosteroids for Myasthenia Gravis

Corticosteroid treatment may have short-term benefit in myasthenia gravis compared with placebo. Level of evidence: "C"

A Cochrane review [Abstract] 1 included 7 small studies with199 participants. A trial of adrenocorticotrophic hormone (43 patients) did not show any advantage compared with placebo for the treatment of ocular myasthenia gravis. Two double-blind trials compared prednisone with placebo for generalised myasthenia gravis. In the first (13 patients), the improvement was slightly greater in the prednisone group at six months. In the second (20 patients) which was a short-term trial, the improvement was significantly greater at two weeks. Two trials compared glucocorticosteroids with azathioprine (41 and 10 patients respectively). In one of these the rate of treatment failure was greater in the prednisone group. In a trial of glucocorticosteroids versus intravenous immunoglobulin (33 patients) no differences in treatment responses were encountered during a treatment period of 14 days. An open trial (39 patients) evaluating different corticosteroid doses revealed a shorter time to improvement in the high-dose group.

Comment: The quality of evidence is downgraded by inconsistency (heterogeneity in patients and outcomes) and imprecise results (limited study size for each comparison).

    References

    • Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005 Apr 18;(2):CD002828. [Assessed as up-to-date: 27 Jun 2010][PubMed]

Primary/Secondary Keywords